Laddar populära aktier...
Redeye leaves a comment following Klaria’s recent announcement of a licensing agreement with CNX The...
Henrik Andersson, who has served as CEO of Northbaze since 2018, has informed the board of directors...
Redeye makes minor revisions to estimates ahead of Enea’s Q4 2024 report due on 30 January 2025.
Taaleri announced today 9 January, that its CEO Peter Ramsay has resigned and will leave his positio...
Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the re...
Duell publishes its Q1/2025 (9/24-11/24) business review on 16th of January.
Q4 report due 11 February We forecast Q4 net sales of SEK 520m & EBITA of SEK 78m We reiterate our f...
Redeye comments on Sivers Semiconductors’ announcement of a new USD5.
Redeye expects a stable Q4 report from Addnode, sharing a lot of similarities with Q3.
All share offer of SEK 58.7/sh accepted, delisting approved More about Tethys and the offer All sha...
Sells Ofir to Jobindex for DKK 20m, or ~DKK 1.0/share.
Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myel...
Solid Q4e ahead, likely to end '24e with a fifth guidance upgrade Market conditions appear unchanged...
Redeye comments on announcing a new pilot involving the renowned Mayo Clinic.
Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explo...
